Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Guidelines on nuclear medicine imaging in neuroblastoma.

Literature DB >> 29938300

Guidelines on nuclear medicine imaging in neuroblastoma.

Zvi Bar-Sever¹, Lorenzo Biassoni², Barry Shulkin³, Grace Kong⁴, Michael S Hofman⁴, Egesta Lopci⁵, Irina Manea⁶, Jacek Koziorowski⁶, Rita Castellani⁷, Ariane Boubaker⁸, Bieke Lambert⁹, Thomas Pfluger¹⁰, Helen Nadel¹¹, Susan Sharp¹², Francesco Giammarile¹³.

Abstract

Nuclear medicine has a central role in the diagnosis, staging, response assessment and long-term follow-up of neuroblastoma, the most common solid extracranial tumour in children. These EANM guidelines include updated information on 123I-mIBG, the most common study in nuclear medicine for the evaluation of neuroblastoma, and on PET/CT imaging with 18F-FDG, 18F-DOPA and 68Ga-DOTA peptides. These PET/CT studies are increasingly employed in clinical practice. Indications, advantages and limitations are presented along with recommendations on study protocols, interpretation of findings and reporting results.

Entities: Chemical Disease Species

Keywords: 123I-MIBG; 18F-DOPA PET/CT; 18F-FDG PET/CT; 68Ga-DOTA TATE PET/CT; Children; Guidelines; Neuroblastoma

Mesh：

Substances：

Year: 2018 PMID： 29938300 DOI： 10.1007/s00259-018-4070-8

Source DB: PubMed Journal: Eur J Nucl Med Mol Imaging ISSN： 1619-7070 Impact factor: 9.236

132 in total

1. Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma.

Authors: Shih-ying Huang; Wesley E Bolch; Choonsik Lee; Henry F Van Brocklin; Miguel H Pampaloni; Randall A Hawkins; Aimee Sznewajs; Steven G DuBois; Katherine K Matthay; Youngho Seo
Journal: Mol Imaging Biol Date: 2015-04 Impact factor: 3.488

Review 2. Pharmacological interference with 123I-metaiodobenzylguanidine: a limitation to developing cardiac innervation imaging in clinical practice?

Authors: A Stefanelli; G Treglia; I Bruno; V Rufini; A Giordano
Journal: Eur Rev Med Pharmacol Sci Date: 2013-05 Impact factor: 3.507

3. Pre-medication to block [(18)F]FDG uptake in the brown adipose tissue of pediatric and adolescent patients.

Authors: Michael J Gelfand; Sara M O'hara; Lois A Curtwright; Joseph R Maclean
Journal: Pediatr Radiol Date: 2005-06-30

4. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases.

Authors: B Shapiro; J E Copp; J C Sisson; P L Eyre; J Wallis; W H Beierwaltes
Journal: J Nucl Med Date: 1985-06 Impact factor: 10.057

5. Neuroblastoma, its natural history and prognosis: a study of 487 cases.

Authors: L M Wilson; G J Draper
Journal: Br Med J Date: 1974-08-03

Review 6. MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma.

Authors: A Boubaker; A Bischof Delaloye
Journal: Q J Nucl Med Mol Imaging Date: 2008-12 Impact factor: 2.346

7. Unusual Tc-99m MDP and I-123 MIBG images in focal pyelonephritis.

Authors: A Jacobs; P Lenoir; M Delree; J Ramet; A Piepsz
Journal: Clin Nucl Med Date: 1990-11 Impact factor: 7.794

8. Iodine-131-metaiodobenzylguanidine and bone scintigraphy for the detection of neuroblastoma.

Authors: B L Shulkin; B Shapiro; R J Hutchinson
Journal: J Nucl Med Date: 1992-10 Impact factor: 10.057

9. Characterization of somatostatin receptors on human neuroblastoma tumors.

Authors: M S O'Dorisio; F Chen; T M O'Dorisio; D Wray; S J Qualman
Journal: Cell Growth Differ Date: 1994-01

Review 10. MIBG in Neuroblastoma Diagnostic Imaging and Therapy.

Authors: Susan E Sharp; Andrew T Trout; Brian D Weiss; Michael J Gelfand
Journal: Radiographics Date: 2016 Jan-Feb Impact factor: 5.333

17 in total

1. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma.

Authors: David Taïeb; Rodney J Hicks; Elif Hindié; Benjamin A Guillet; Anca Avram; Pietro Ghedini; Henri J Timmers; Aaron T Scott; Saeed Elojeimy; Domenico Rubello; Irène J Virgolini; Stefano Fanti; Sona Balogova; Neeta Pandit-Taskar; Karel Pacak
Journal: Eur J Nucl Med Mol Imaging Date: 2019-06-29 Impact factor: 9.236

2. Does the Incremental Value of ¹²³I-Metaiodobenzylguanidine SPECT/CT over Planar Imaging Justify the Increase in Radiation Exposure?

Authors: Dorra Ben-Sellem; Naima Ben-Rejeb
Journal: Nucl Med Mol Imaging Date: 2021-07-07

3. The prognostic value of ¹⁸F-FDG PET/CT intra-tumoural metabolic heterogeneity in pretreatment neuroblastoma patients.

Authors: Jun Liu; Yukun Si; Ziang Zhou; Xu Yang; Cuicui Li; Luodan Qian; Li Juan Feng; Mingyu Zhang; Shu Xin Zhang; Jie Liu; Ying Kan; Jianhua Gong; Jigang Yang
Journal: Cancer Imaging Date: 2022-07-05 Impact factor: 5.605

4. Adrenocortical Tumors and Pheochromocytoma/Paraganglioma Initially Mistaken as Neuroblastoma-Experiences From the GPOH-MET Registry.

Authors: Michaela Kuhlen; Christina Pamporaki; Marina Kunstreich; Stefan A Wudy; Michaela F Hartmann; Mirko Peitzsch; Christian Vokuhl; Guido Seitz; Michael C Kreissl; Thorsten Simon; Barbara Hero; Michael C Frühwald; Peter Vorwerk; Antje Redlich
Journal: Front Endocrinol (Lausanne) Date: 2022-06-17 Impact factor: 6.055

Review 5. Clinical application of ¹⁸F-DOPA PET/TC in pediatric patients.

Authors: Gabriele Masselli; Emanuele Casciani; Cristina De Angelis; Saadi Sollaku; Gianfranco Gualdi
Journal: Am J Nucl Med Mol Imaging Date: 2021-04-15

Review 6. The new international neuroblastoma response criteria.

Authors: Katharine E Orr; Kieran McHugh
Journal: Pediatr Radiol Date: 2019-10-16

Review 7. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms.

Authors: Valentina Ambrosini; Jolanta Kunikowska; Eric Baudin; Lisa Bodei; Catherine Bouvier; Jaume Capdevila; Marta Cremonesi; Wouter W de Herder; Clarisse Dromain; Massimo Falconi; Melpomeni Fani; Stefano Fanti; Rodney J Hicks; Levent Kabasakal; Gregory Kaltsas; Val Lewington; Silvia Minozzi; Michela Cinquini; Kjell Öberg; Wim J G Oyen; Dermot O'Toole; Marianne Pavel; Philippe Ruszniewski; Aldo Scarpa; Jonathan Strosberg; Anders Sundin; David Taïeb; Irene Virgolini; Damian Wild; Ken Herrmann; James Yao
Journal: Eur J Cancer Date: 2021-02-12 Impact factor: 9.162

Guidelines on nuclear medicine imaging in neuroblastoma.

1. Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma.

Review 2. Pharmacological interference with 123I-metaiodobenzylguanidine: a limitation to developing cardiac innervation imaging in clinical practice?

3. Pre-medication to block [(18)F]FDG uptake in the brown adipose tissue of pediatric and adolescent patients.

4. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases.

5. Neuroblastoma, its natural history and prognosis: a study of 487 cases.

Review 6. MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma.

7. Unusual Tc-99m MDP and I-123 MIBG images in focal pyelonephritis.

8. Iodine-131-metaiodobenzylguanidine and bone scintigraphy for the detection of neuroblastoma.

9. Characterization of somatostatin receptors on human neuroblastoma tumors.

Review 10. MIBG in Neuroblastoma Diagnostic Imaging and Therapy.

1. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma.

2. Does the Incremental Value of ¹²³I-Metaiodobenzylguanidine SPECT/CT over Planar Imaging Justify the Increase in Radiation Exposure?

3. The prognostic value of ¹⁸F-FDG PET/CT intra-tumoural metabolic heterogeneity in pretreatment neuroblastoma patients.

4. Adrenocortical Tumors and Pheochromocytoma/Paraganglioma Initially Mistaken as Neuroblastoma-Experiences From the GPOH-MET Registry.

Review 5. Clinical application of ¹⁸F-DOPA PET/TC in pediatric patients.

Review 6. The new international neuroblastoma response criteria.

Review 7. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms.

Review 8. [Radiological imaging of neuroblastoma].

9. Comparison Between Diffusion-Weighted MRI and ¹²³ I-mIBG Uptake in Primary High-Risk Neuroblastoma.

10. ¹²⁴I-MIBG PET/CT to Monitor Metastatic Disease in Children with Relapsed Neuroblastoma.

Review 2. Pharmacological interference with 123I-metaiodobenzylguanidine: a limitation to developing cardiac innervation imaging in clinical practice?

Review 6. MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma.

Review 10. MIBG in Neuroblastoma Diagnostic Imaging and Therapy.

Review 5. Clinical application of 18F-DOPA PET/TC in pediatric patients.

Review 6. The new international neuroblastoma response criteria.

Review 7. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms.

Review 8. [Radiological imaging of neuroblastoma].

Review 5. Clinical application of ¹⁸F-DOPA PET/TC in pediatric patients.